# Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

> **NCT06571214** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Nanjing University** · enrollment: 300 (estimated)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)
- **DRUG:** Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)

## Key facts

- **NCT ID:** NCT06571214
- **Lead sponsor:** Nanjing University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571214, "Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06571214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*